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BACKGROUND: With the increasing incidence of breast cancer worldwide, in particular in southeast Asia (including Korea), and the
common use of anthracyclines in the adjuvant and metastatic settings, the occurrence of Hepatitis B virus (HBV) reactivation may
develop in this patient population. The use of prophylactic antiviral agents in cancer patients may result in a reduced HBV
exacerbation. The purpose of the current study was to assess the efficacy of prophylactic lamivudine in reducing the incidence and
severity of HBV reactivation in post-operative breast cancer patients undergoing adjuvant doxorubicin-containing chemotherapy.
METHODS: The medical records of patients undergoing anthracycline-based adjuvant chemotherapy at Samsung Medical Center
between January 2001 and September 2008 were reviewed.
RESULTS: From the database, 1912 breast cancer patients who had received anthracycline-based adjuvant chemotherapy were
identified. Of 131 patients who were HBV surface antigen positive, 55 and 76 did and did not receive prophylactic lamivudine,
respectively. In all, 30 patients (23%) developed hepatitis during doxorubicin-containing adjuvant chemotherapy. Of the 30 patients,
5 (9%) were in the prophylactic lamivudine group and 25 (33%) in the control group (P¼0.001). In the prophylactic lamivudine
group, there was significantly less HBV reactivation (1 patient (2%) vs 20 patients (16%); P¼0.002), less disruption of chemotherapy
(7 vs 14%; P¼0.04), and less severe hepatitis (0 vs 17%; P¼0.002).
CONCLUSION: Prophylactic lamivudine significantly reduced the incidence and severity of HBV reactivation in breast cancer patients
undergoing anthracycline-based adjuvant chemotherapy.
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Hepatitis B virus (HBV) infection is a global health problem and
particularly endemic in southeast Asia and the western Pacific
regions, where 48% of the population are chronic HBV carriers
(Lok et al, 1987; Lee, 1997). The prevalence of HBV surface antigen
(HbsAg) in Korea is 5.1% in men and 4.1% in women according to
the National Health and Nutrition Survey (Lee et al, 2002).
Reactivation of HBV replication with an increase in serum HBV
DNA and alanine aminotransferase (ALT) activity has been
reported in 20–50% of hepatitis B carriers undergoing cytotoxic
chemotherapy for cancer treatment (Yeo et al, 2000, 2003, 2004b;
Idilman et al, 2004; Lok and McMahon, 2007). During intense
cytotoxic therapy, immunosuppression may allow enhanced HBV
replication, which results in a widespread infection of hepatocytes.
With the subsequent restoration of immune function due to the
withdrawal of cytotoxic or immunosuppressive therapy, there is a
rapid immune-mediated destruction of HBV-infected hepatocytes,
which is manifested clinically as asymptomatic self-limiting
hepatitis, severe progressive hepatic failure, and even death (Lau
et al, 2003; Mindikoglu et al, 2006). The prognosis of cancer may
be compromised by disruption in anticancer treatment during the
course of hepatitis, with a delay in treatment cycles and premature
termination of chemotherapy (Lok et al, 1991).
HBV reactivation has been reported frequently in patients
diagnosed to have lymphoma or breast cancer and those who have
received anticancer chemotherapy, and in this setting, the use of
anthracyclines and corticosteroids as part of the chemotherapeutic
combination and/or anti-emetic pre-medication were the factors
shown to be associated with HBV reactivation (Khokhar et al, 2009).
The use of antiviral agents in cancer patients has been shown to
reduce HBV reactivation and to prevent the associated fatal
complications. Consensus guidelines by the American Association
for the Study of Liver Diseases (AASLD) recommend the use of
prophylactic antiviral agents for HBsAg-positive cancer patients
undergoing cytotoxic chemotherapy (Lok and McMahon, 2007).
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sLamivudine, a cyclic nucleoside analogue, is effective in
suppressing HBV DNA, normalising liver enzymes, and improving
the histological features in HBeAg-positive and -negative/HBV DNA-
positive patients. This effect suggests that prophylactic antiviral therapy
with lamivudine reduces the risk of HBV reactivation and prevents the
associated fatal hepatic complications with no myelosuppressive effect
in patients already exposed to an immunosuppressive and cytotoxic
treatment. The use of prophylactic lamivudine in cancer patients
undergoing chemotherapy has recently been reported in several small
series, which were based mainly on patients with lymphomas or a
heterogeneous group of various cancers treated with steroids and
rituximab. The findings of the studies suggested that the antiviral agent,
lamivudine, may reduce HBV reactivation and the associated morbi-
dity (Lok et al, 1991; Lau et al, 2003; Yeo et al, 2004b; Mindikoglu et al,
2006). Furthermore, according to a recent study involving patients in
Hong Kong, prophylactic lamivudine treatment in post-operative and
metastatic breast cancers significantly reduced the incidence of HBV
reactivation from 31 to 7%, with a decrease in hepatitis from all causes
from 59 to 13%. In addition, disruption in chemotherapy was
significantly reduced from 46 to 16% (Yeo et al, 2004b). However,
the population also included patients with hepatic metastasis, thus the
results should be interpreted with caution. Furthermore, many studies
involving prophylactic antiviral therapy have been limited by small
sample size, heterogeneity in tumour type, heterogeneous disease
settings (adjuvant or palliative treatment), and varying chemotherapy
regimens, and it is difficult to determine how effective lamivudine is in
breast cancer patients receiving adjuvant chemotherapy, especially in
patients treated with a doxorubicin-containing regimen, the most
commonly used and effective agent in adjuvant treatment.
The objective of the present study was to assess the efficacy of
prophylactic lamivudine in reducing the incidence and severity of
HBV reactivation in post-operative breast cancer patients under-
going adjuvant doxorubicin-containing chemotherapy.
PATIENTS AND METHODS
At the time of surgery, liver function tests, sonography of the liver,
and serological examinations for hepatitis B (HBsAg, anti-HBs,
and anti-HBc IgG) were performed as a screening procedure. For
the duration of adjuvant chemotherapy, complete blood cell counts
and liver function tests were performed before each cycle. When
exacerbation of hepatitis B was documented, appropriate manage-
ment for the treatment of hepatitis was followed. Planned
chemotherapies were modified (doses and schedules) according
to the severity of hepatitis. The 131 patients were divided into two
groups (patients who did (n¼55) and did not (n¼76) receive
prophylactic lamivudine). Most of the HBsAg-positive patients in
our Institute were treated with lamivudine as a pre-emptive
antiviral therapy since 2005 (post-lamivudine era) compared with
2005 (pre-lamivudine era). We analysed the clinical manifestations
with the laboratory findings of hepatitis during and after adjuvant
chemotherapy. Our study protocol was approved by the Institu-
tional Review Board of Samsung Medical Center.
Hepatitis serology and HBV DNA assay
Hepatitis B was detected by commercial enzyme immunoassay
(HBsAg; Abbott, Chicago, IL, USA). The status of hepatitis B e-antigen
(HBeAg, AxSYM; Abbott) and HBV DNA were evaluated in HBsAg-
positive patients. Serum HBV DNA levels were assessed using the
Digene Hybrid Capture II HBV DNA test (Digene Corp., Gaithers-
burg, MD, USA) with a limit of detection of 0.5–6000pgml
 1.
Definitions
The following definitions according to Lok and McMahon (2007)
and subsequently modified by Lok and McMahon (2009) were
applied. ‘Hepatitis’ was defined as a X3 times increase in ALT that
exceeds the upper normal limit (UNL, o40IUl
 1) or an absolute
increase of ALT to 4100IUl
 1 when compared with the baseline
pre-chemotherapy value. Hepatitis, attributable to ‘HBV reactiva-
tion,’ was defined as an increase in the HBV DNA level X10 times
when compared with the baseline level or an absolute increase in
the HBV DNA level that exceeded 1000 10
6g.E.ml
 1 in the
absence of other systemic infections. The severity of hepatitis was
defined as ‘mild,’ ‘moderate,’ and ‘severe’ when the rise in ALT was
p2  the UNL, 42  and p5  the UNL, and 45  the UNL,
respectively. ‘A disruption in chemotherapy’ was defined as a
premature termination of chemotherapy or a delay of X8 days of
chemotherapy between cycles.
Adjuvant chemotherapy and use of lamivudine
The anthracycline-based chemotherapy regimens included
AC (doxorubicin plus cyclophosphamide), FAC (5-FU plus doxo-
rubicin plus cyclophosphamide), and AC followed by four cycles of
a taxane (paclitaxel (175mgm
 2) or docetaxel (75mgm
 2)). The
AC chemotherapy consisted of doxorubicin (60mgm
 2) and
cyclophosphamide (600mgm
 2) i.v. push on day 1 for four cycles.
The FAC consisted of cyclophosphamide (500mgm
 2), doxorubi-
cin (50mgm
 2), and 5-FU (500mgm
 2) i.v. push on day 1 for six
cycles. The chemotherapy cycles were repeated every 21 days.
Patients with primary tumours X5cm in size or X4 positive
nodes, and patients who underwent breast-conserving surgery
were treated with adjuvant radiotherapy after chemotherapy.
Patients with ER- or PR-positive tumours were treated for 5 years
with tamoxifen or aromatase inhibitor therapy after adjuvant
chemotherapy, according to the patient’s menopausal status.
Patients in the prophylactic lamivudine group commenced
lamivudine (100mg orally daily) within 7 days before the start of
chemotherapy. For patients with renal insufficiency, the daily
lamivudine dose was adjusted according to creatinine clearance. In
the control group, prophylactic lamivudine was not administered.
All of the patients received lamivudine after HBV reactivation.
Statistical analysis
Clinical and laboratory variables were compared across groups
using the Fisher’s exact test or Pearson’s w
2 test where appropriate
for dichotomous variables, and the Mann–Whitney U-test for
continuous variables. A P-value o0.05 was considered statistically
significant. The Cox proportional hazards regression model was
used in univariate and multivariate analyses to identify the most
significant prognostic factors for HBV reactivation. The logistic
regression model was created using an unconditional procedure,
and the probability was set at 0.05 for entry and 0.10 for removal.
The hazard ratio (HR) and 95% confidence interval (CI) were
estimated with a pre-determined reference risk of 1.0. SPSS
software (version 17.0; SPSS Inc., Chicago, IL, USA) was used for
statistical analyses.
RESULTS
Patient characteristics
Among 3189 newly diagnosed breast cancer patients who under-
went curative surgery between January 2001 and September 2008
at Samsung Medical Center, 1912 receiving anthracycline-based
adjuvant chemotherapy were identified. All 3189 patients under-
went HBsAg testing. In Korea, all patients who received elective
surgery routinely underwent HBsAg testing (at least HBsAg/sAb)
before surgery. Of the 1912 patients, 131 HBsAg-positive patients
(6.9%) with normal hepatic function (serum levels of aspartate
aminotransferase (AST), ALT, alkaline phosphatase, albumin, and
total and direct bilirubin) were identified (Figure 1). None of the
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spatients had a previously received anti-HBV therapy. In all, 55 and
75 patients did and did not receive prophylactic lamivudine,
respectively. The patient’s characteristics are provided in Table 1.
There were no significant differences with respect to age, level of
ALT, total bilirubin, and adjuvant radiation therapy. The baseline
AST level had a tendency to be higher and the albumin level had a
tendency to be lower in the prophylactic lamivudine group
(Table 1).
Biochemical and clinical outcomes in the two groups of
patients
The prophylactic lamivudine group Patients received lamivudine
(100mg daily) for a median duration of 185 days (range, 30–1540
days). Treatment was continued for a median of 2 months (range,
0–47 months) after completion of chemotherapy. The median
number of chemotherapy cycles was 6 (range, 4–8 cycles). Two
patients developed a tyrosine–methionine–aspartate–aspartate
(YMDD) mutation during lamivudine therapy, and therefore
received adefovir dipivoxil (10mg) add-on to lamivudine. The
total duration of lamivudine therapy in these two patients was 1540
days and 745 days, respectively.
Five patients (9%) developed hepatitis during or after chemo-
therapy and one patient (2%) developed HBV reactivation 15 days
after cessation of lamivudine (Table 2). The severity of hepatitis
was mild in three patients and moderate in two patients. In one
case of HBV reactivation, the severity of hepatitis was moderate.
The median duration from initiation of chemotherapy to
development of hepatitis was 68 days (range, 44–351 days).
Disruption in chemotherapy occurred in two patients (3%). There
were no mortalities among patients who received prophylactic
lamivudine. The antiviral agents were well tolerated and were not asso-
ciated with any unexpected or additional toxicities to chemotherapy.
The control group The median number of chemotherapy cycles
was six (range, 1–9 cycles). In all, 25 of the 76 control group
patients (33%) developed hepatitis during or after chemotherapy.
Among the 75 patients, 16 (21%) had HBV reactivation. The
severity of hepatitis was mild in 3, moderate in 7, and severe in
4197 newly diagnosed breast cancer pts who received
definitive surgery from Jan 2001 to Sep 2008 at SMC
3189 newly diagnosed breast cancer pts who received
adjuvant chemotherapy after definitive surgery
from Jan 2001 to Sep 2008 at SMC
992 patients who received adjuvant
chemotherapy without anthracycline
285 pts unavailable medical record or lost f/u
1912 pts who received anthracycline-containing adjuvant
chemotherapy after definitive surgery
from Jan 2001 to Sep 2008 at SMC
131 patients with HBsAg (+)
76 pts, control group 55 pts, prophylactic lamivudine group
Figure 1 Patients’ cohort. F/u, follow up.
Table 1 Comparison of clinical characteristics between the ‘control’ and
the ‘prophylactic lamivudine’ groups in the HBsAg-positive breast cancer
patients
Control
group
Prophylactic
lamivudine group
N % N % P-value
No. of patients 76 58 55 42
Age (years) median, range 46 (30–69) 48 (30–68) 0.18
Pre-chemotherapy status
AST (IUl
 1) (0–40)
a,
mean
24 30 0.09
ALT (IUl
 1) (0–40)
a,
mean
25 25 0.25
Total bilirubin (mgdl
 1)
(0.2–1.5)
a, mean
0.5 0.6 0.11
Albumin (gdl
 1)
(3.5–5.2)
a, mean
4.2 4.0 0.06
Chemotherapy regimen
AC 17 22 3 5
FAC 28 37 25 45 0.02
AC-D / T 3 14 1 2 75 0
Steroid use for anti-emetics 33 45 28 51 0.48
Stage
11 1 1 5 9 1 6
2 39 51 32 58 0.56
3 2 63 4 1 42 6
Adjuvant RT 12 16 4 7 0.18
Abbreviations: AC¼doxorubicin + cyclophosphamide; AC-D/T¼AC followed
by docetaxel or paclitaxel; ALT¼alanine-aminotransferase; AST¼aspartate amino-
transferase; FAC¼5-FU + doxorubicin + cyclophosphamide; HbsAg¼hepatitis B
virus surface antigen; RT¼radiation therapy.
aNormal range.
Table 2 Morbidity and mortality in the ‘control’ and the ‘prophylactic
lamivudine’ groups
Control
group
Prophylactic
lamivudine
group
N % N % P-value
No. of patients 76 55
Overall morbidity
Incidences of hepatitis 25 33 5 9 0.001
Hepatitis attributable to
HBV reactivation
16 21 1 2 0.001
Severity of hepatitis 0.001
Mild (HBV reactivation) 3 (2) 4 3 (0) 7
Moderate (HBV
reactivation)
7 (1) 10 2 (1) 3
Severe (HBV reactivation) 15 (13) 19 0 (0) 0
HBV DNA at reactivation
(mean, pg)
128970 93567 0.132
Disruptions of chemotherapy 11 14 2 3 0.04
Premature termination 23 00
Hepatitis due to HBV
reactivation
23 00
Completion of chemotherapy
with delay of 48 days
91 2 23
Hepatitis, all cases 9 12 2 3
Hepatitis due to HBV
reactivation
57 00
Other causes 0 0 0 0
Overall mortality related to
hepatitis B reactivation
00 00
Median no. of chemotherapy
cycles received (range)
6.1 (1–9) 6.8 (4–8) 0.018
Abbreviation: HBV¼Hepatitis B virus.
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s15 patients. In patients with HBV reactivation, 3 had mild
hepatitis, 7 had moderate hepatitis, and 15 had severe hepatitis.
One patient died because of rapid progression of recurrent breast
cancer during third-line palliative chemotherapy, which was not
related to hepatitis B reactivation. Disruption in chemotherapy
occurred in 11 patients. Two patients had premature termination
of chemotherapy, and nine patients completed chemotherapy with
interval delays (Table 2).
Of the 16 patients who developed HBV reactivation, 14 received
lamivudine and 2 received entecarvir as a therapeutic measure at
the time of HBV reactivation. Despite this, 11 patients (14%) had
disruptions in chemotherapy, 2 had premature termination of
chemotherapy, and 9 had prolonged interval delays.
Comparison of outcomes between the two groups In the
prophylactic lamivudine group, there was significantly less HBV
reactivation (2 vs 21% in the controls, P¼0.001), a lower incidence
of hepatitis (9 vs 33%, P¼0.001), and less disruption in
chemotherapy (3 vs 14%, P¼0.04).
Prognostic factors for HBV reactivation Univariate analysis
showed a lower rate of HBV reactivation in patients who received
prophylactic lamivudine than in those who did not (21 vs 2%,
respectively; P¼0.001). There was no independent prognostic
factor for HBV reactivation other than prophylactic lamivudine.
Multivariate analysis showed that ‘no use of prophylactic
lamivudine’ was a significant risk factor (HR, 14.6; 95% CI,
1.89–114.13; P¼0.031; Table 3).
DISCUSSION
In the current study, we confirmed the importance of prophylactic
lamivudine treatment in HBV carriers receiving adjuvant anthra-
cycline-based chemotherapy for post-operative early breast cancer.
Considering that anthracyclines are some of the most widely used
and effective drugs to treat patients with breast cancer in the
adjuvant setting as well as patients with metastatic disease (Bennett
et al, 1988; Henderson et al, 1989; Green et al, 1996; Fossati et al,
1998; Pai and Nahata, 2000; Crown et al, 2002), the number of
reports is limited (Lai et al, 1998; Rossi et al, 2001; Lee et al, 2003).
These results included a heterogeneous population in terms of the
use of a prophylactic antiviral agent. Indeed, this is the first study
involving the role of antiviral prevention in breast cancer patients
receiving anthracycline-based adjuvant chemotherapy.
Pre-emptive antiviral therapy has been used as a potential
benefit of antiviral agents for HBV as lamivudine had been known,
although still there are lacking data to support the pre-emptive
therapy for this clinical setting. Actually, most of the HBsAg-
positive patients have been treated with lamivudine as pre-emptive
antiviral therapy after 2005 in our Institute (post-lamivudine era).
Before 2005, we did not use lamivudine as pre-emptive antiviral
therapy (pre-lamivudine era). Thus, this clinical decision was
made not by each physician’s preference, but by the ‘changing
paradigm’.
Using a prophylactic lamivudine significantly reduced the
incidence of hepatitis from 33 to 9%, HBV reactivation from
21 to 2%, and disruption of chemotherapy from 14 to 3% in HBV-
carrier breast cancer patients who are undergoing anthracycline-
based adjuvant chemotherapy. The implication of this study focused
on breast cancer patients receiving anthracyline-containing
adjuvant chemotherapies. Thus, morbidity and mortality caused
by adjuvant treatment should not override cancer outcomes.
In contrast, in the control group, although all 16 patients who
developed HBV reactivation received therapeutic antiviral treat-
ment, 2 of the 16 patients (13%) had premature termination of
chemotherapy. Therefore, prophylactic antiviral treatment is more
important than therapeutic interventions after viral reactivation
with respect to cancer outcome in HBV carriers undergoing
anthracycline-based chemotherapy.
Selection of the population of patients receiving adjuvant
chemotherapy can reduce bias, which may be underestimated or
overestimated hepatitis itself associated with hepatic metastasis. In
addition, assuming the popularity of doxorubicin and cyclophos-
phamide in this common homogeneous clinical setting, the role of
lamivudine prophylaxis appeared to be effective in immuno-
suppressive therapies. This finding is supported by the data, in
which the use of anthracycline-contating chemotherapy is iden-
tified as a risk factor in reactivation of hepatitis B (Yeo et al,
2004a). Although there were no mortalities in either group, severe
hepatitis occurred in 15 patients (13%) in the control group,
suggesting the possibility that mortality would occur. We should
thus pay attention to the possibility of mortality related to HBV
reactivation during adjuvant chemotherapy in this population of
curable patients. As level I evidence, the AASLD guidelines
recommend that lamivudine can be used even if the anticipated
duration of treatment is short (p12 months) and serum HBV DNA
is not detectable at baseline. Tenofovir or entecavir is preferred if a
longer duration of treatment is anticipated (level III evidence).
Thus far, most of the studies have focused on the effect of
prophylactic lamivudine treatment regardless of the anticipated
duration of the treatment. Therefore, we also selected an adjuvant
setting to precisely assess the efficacy of prophylactic lamivudine
according to the recommendations.
The AASLD guidelines recommend beginning antiviral therapy
7 days before chemotherapy and continuing for 6 months (level III
evidence; Yeo et al, 2004a,b). The duration of treatment has not
been established. In the case of chronic HBV infection, prolonged
lamivudine therapy exceeding 6 months in duration has been
associated with an increased likelihood of treatment-emergent
HBV variants with a YMDD mutation, appearing in 12–20% in the
first year of treatment (Lau et al, 2003; Yeo et al, 2004b). In the
current study, the median duration of lamivudine treatment was
185 days, and 30 of 55 patients received prolonged lamivudine
treatment exceeding 6 months. Among 30 patients, a YMDD
mutation emerged in two patients (7%). One case occurred in the
course of using lamivudine for 24 months and the other case
occurred in the course of using lamivudine for 51 months. Since
then, the patients have received combination treatment with
lamivudine and adefovir. Fortunately, there were no occurrences of
HBV reactivation since that time. Accordingly, despite the
potential benefits of the prophylactic approach, careful clinical
monitoring is still required. Furthermore, there is a need to
emphasise the implication, especially in patients in the adjuvant
treatment setting. We must consider the variability of the
prevalence of hepatitis B, even though a recent ASCO guideline
update does not recommend prophylaxis universally (Artz et al,
2010). Although the prevalence of chronic HBV infection is
decreasing, it is still a major aetiology of liver cirrhosis and
hepatocellular carcinoma in Korea (Chae et al, 2009). Hepatitis B
reactivation can be a cause of major morbidity and mortality in
patients who receive chemotherapy in this endemic area. Thus, we
need to consider the area to adapt the recommendations
universally. In addition, large prospective randomised trials are
needed to confirm the value of pre-emptive therapy in this setting.
Table 3 Multivariate logistic-regression analysis on reactivation of
hepatitis B
P-value HR 95% CI
No use of prophylactic lamivudine 0.031 14.6 1.89 114.13
Radiation 0.891 1.4 0.80 4.52
Stage 0.752 1.6 0.02 8.23
Abbreviations: CI¼confidence interval; HR¼hazard ratio.
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sWe confirmed the efficacy of prophylactic lamivudine with
respect to reducing the incidence and severity of HBV reactivation
in patients undergoing adjuvant anthracycline-based chemo-
therapy in a homogeneous group of breast cancer patients. We
fully expect that updated cancer treatment guidelines will emerge
soon, including guidelines of prophylactic antiviral treatment for
each cancer, because suggesting the need for prophylactic antiviral
treatment for each cancer is a significant task.
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